Posted by msmash from Slashdot
From the how-about-that department: Google has overtaken IBM to become the leader in generative AI-related patents and also leads in the emerging area of agentic AI, according to data from IFI Claims. Axios: In the patents-for-agents U.S. rankings, Google and Nvidia top the list, followed by IBM, Intel and Microsoft, according to an analysis released Thursday.
Globally, Google and Nvidia also led the agentic patents list, but three Chinese universities also make the top 10, highlighting China's place as the chief U.S. rival in the field. In global rankings for generative AI, Google was also the leader -- but six of the top 10 global spots were held by Chinese companies or universities. Microsoft was No. 3, with Nvidia and IBM also in the top 10.
Posted by BeauHD from Slashdot
From the all-in-on-AI department: Nvidia-backed CoreWeave plans to spend up to $23 billion this year on AI infrastructure and data center capacity, as it aims to meet the booming demand from clients. Reuters reports: The heavy spending plan weighed on its shares, which fell 5% after surging as much as 11% on better-than-expected revenue in its first results as a public company after debuting on the Nasdaq in March. The company's projected capital expenditure of between $3 billion and $3.5 billion for the second quarter was way above its revenue expectation of $1.06 billion to $1.1 billion. "While the revenue from Microsoft is likely secure for the next three years, CoreWeave represents overflow capacity for Microsoft, which may not need that capacity in the future," D.A. Davidson analyst Gil Luria said.
The company's revenue backlog was $25.9 billion as of March 31, with its five-year deal with OpenAI adding $11.2 billion to the pile up. As part of the deal signed in March, CoreWeave will provide AI infrastructure to OpenAI, while the ChatGPT maker will get a stake. CoreWeave expects annual revenue of $4.9 billion to $5.1 billion, above analysts' expectation of $4.61 billion, according to data compiled by LSEG. It reported revenue of $981.6 million for the first quarter, beating the estimate of $852.9 million.
Posted by BeauHD from Slashdot
From the what-to-expect department: Montana has passed a bill allowing licensed clinics to offer experimental medical treatments that haven't been approved by the FDA, provided the drugs have passed phase I safety trials. MIT Technology Review reports: The bill, which was passed by the state legislature on April 29 and is expected to be signed by Governor Greg Gianforte, essentially expands on existing Right to Try legislation in the state. But while that law was originally designed to allow terminally ill people to access experimental drugs, the new bill was drafted and lobbied for by people interested in extending human lifespans -- a group of longevity enthusiasts that includes scientists, libertarians, and influencers. These longevity enthusiasts are hoping Montana will serve as a test bed for opening up access to experimental drugs. [...]
Supporters of the bill say it gives individuals the freedom to make choices about their own bodies. At the same event, bioethicist Jessica Flanigan of the University of Richmond said she was "optimistic" about the measure, because "it's great any time anybody is trying to give people back their medical autonomy." Ultimately, they hope that the new law will enable people to try unproven drugs that might help them live longer, make it easier for Americans to try experimental treatments without having to travel abroad, and potentially turn Montana into a medical tourism hub.
< This article continues on their website >